In addition to PD-L1, the non-genetic mechanisms underlying PD-L2 expression and function in solid tumors and hematologic malignancies should be investigated, as both ligands compete for the same receptor, PD1, and therefore the relative levels of both proteins may impact certain immunotherapy approaches. This evidence concerns the gene PDCD1LG2 and hematologic disorder.